This financing is an excellent way to minimize dilution and sets us for an optimal situation if there is a buyout of RVX coming.
However, it will act as an effective cap to any positive news from the Dementia data on Dec 5. So we can forget about joy on a daily mark to market basis for the time being.
Post the dementia data, our next hope is for some buyer to show up...hopefully after the FDA letter arrives mid December.